Abstracts tagged "pregnancy"

Abstract Number: 2290 • 2019 ACR/ARP Annual Meeting
A Multicentre Study of 244 Pregnancies in Women with Undifferentiated Connective Tissue Disease: Foetal/Perinatal and Maternal Outcomes and Disease Evolution Towards a Definite Connective Tissue Disease
Massimo Radin¹, Karen Schreiber ², Irene Cecchi ¹, Alessandra Bortoluzzi ³, Francesca Crisafulli ⁴, Cristiano M. De Freitas ⁵, Beatrice Bacco ¹, Elena Rubini ¹, Silvia Grazietta Foddai ¹, Melissa Padovan ³, Silvia Gallo Cassarino ¹, Franco Franceschini ⁶, Danieli Andrade ⁷, Chiara Benedetto ⁸, Marcello Govoni ⁹, Tiziana Bertero ¹, Luca Marozio ¹, Dario Roccatello ¹, Laura Andreoli ⁴ and Savino Sciascia ¹⁰, ¹University of Turin, Turin, Italy, ²Department of Rheumatology, Copenhagen University Hospital, Copenhagen, Denmark, ³University of Ferrara, Ferrara, Italy, ⁴University of Brescia, Brescia, Italy, ⁵Universidade de Sao Paolo, San Paolo, Brazil, ⁶Rheumatology and Clinical Immunology, Spedali Civili and Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy, Brescia, Italy, ⁷Hospital das Clinicas, Faculdade de Medicina, Universidade de São Paulo, Sao Paulo, Brazil, ⁸University of Turin, Turin, Piemonte, Italy, ⁹University of Ferrara, Rheumatology Unit, Ferrara, Italy, ¹⁰Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Torino, Italy
Background/Purpose: Undifferentiated connective tissue disease(UCTD) represents a common autoimmune condition in clinical practice, however, therapeutic strategies and follow-up are mostly based on clinician expertise. Little…
Abstract Number: 144 • 2019 ACR/ARP Annual Meeting
Antiphospholipid Syndrome-Associated Preeclampsia Is Defined by a Distinct Clinical Phenotype
Shashank Cheemalavagu¹, Beth Wallace ², Wendy Marder ³, Jason Knight ⁴ and Andrew Vreede ⁵, ¹Department of Internal Medicine, Michigan Medicine, Ann Arbor, MI, ²Center for Clinical Management Research, VA Ann Arbor Healthcare System; Division of Rheumatology, Department of Internal Medicine, Michigan Medicine, Ann Arbor, MI, ³Division of Rheumatology, Department of Internal Medicine, Michigan Medicine, Ann Arbor, ⁴Division of Rheumatology, Department of Internal Medicine, Michigan Medicine, Ann Arbor, MI, ⁵Division of Rheumatology, Department of Internal Medicine, Michigan Medicine; Rheumatology Section, VA Ann Arbor Health System, Ann Arbor, MI
Background/Purpose: Antiphospholipid syndrome (APS) significantly increases risk of preeclampsia. It is assumed that APS is associated with a subset of severe preeclampsia, HELLP (Hemolysis; Elevated…
Abstract Number: 2292 • 2019 ACR/ARP Annual Meeting
Disease Flares of Rheumatoid Arthritis During Pregnancy: What Is the Impact of Stopping bDMARDs at the Beginning of Pregnancy?
Maria Chiara Gerardi¹, Laura Andreoli ¹, Antía García-Fernández ², Chiara Bazzani ³, MATTEO FILIPPINI ³, MICAELA FREDI ¹, ROBERTO GORLA ³, Maria Grazia Lazzaroni ⁴, Cecilia Nalli ³, MARCO TAGLIETTI ⁵, SONIA ZATTI ⁶, ANDREA LOJACONO ⁶, Franco Franceschini ¹ and Angela Tincani ¹, ¹Rheumatology and Clinical Immunology, Spedali Civili and Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy, Brescia, Italy, ²Ramon y Cajal University Hospital, Madrid, Spain, Madrid, Madrid, Spain, ³Rheumatology and Clinical Immunology, Spedali Civili, Brescia, Italy, Brescia, Italy, ⁴Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy., Brescia, Italy, ⁵[email protected], Brescia, Italy, ⁶Obstetrics and Gynaecology, Spedali Civili and University of Brescia, Brescia, Italy, Brescia, Italy
Background/Purpose: During pregnancy, patients with rheumatoid arthritis (RA) can experience flares that might influence pregnancy outcomes. We aimed at assessing disease course during pregnancy and…
Abstract Number: 1075 • 2019 ACR/ARP Annual Meeting
The Impact of Race on Birth Outcomes Among Women with Autoimmune Rheumatic Diseases
Lena Sabih¹, Jennifer Strouse ¹, Nichole Nidey ², Gretchen Bandoli ³, Rebecca Baer ⁴, Sky Feuer ⁵, Laura Jelliffe-Pawlowski ⁵, Christina Chambers ⁶, Kelli Ryckman ² and Namrata Singh ⁷, ¹University of Iowa Hospitals and Clinics, Iowa City, ²UIOWA, Iowa City, ³University of California, San Diego, La Jolla, ⁴UCSD, La Jolla, ⁵UCSF, San Francisco, ⁶UCSD, San Diego, ⁷University of Iowa, Iowa City
Background/Purpose: Autoimmune rheumatic diseases (ARDs) are associated with adverse pregnancy outcomes (APOs). There are only a small number of studies that have looked at the…
Abstract Number: 2297 • 2019 ACR/ARP Annual Meeting
Anti-TNF-α Exposure During Pregnancy: Impact on the Neonate’s Immune System
Yiyi Luo ¹, Andrea Pluma ², Raul Castellanos-Moreira³, Estefania Moreno ⁴, Nuria Baños ⁵, Sebastian DC Rodriguez-Garcia ⁶, Angela Deyà-Martínez ¹, Ana Pilar Garcia-Garcia ¹, Mireia Torres ⁷, Dolors Grados ⁸, Manel Casellas ⁹, Manel Juan ¹, Ana Esteve-Sole ¹ and Laia Alsina ¹⁰, ¹Immunology Department. Center for Biomedical Diagnosis. Hospital Clínic of Barcelona IDIBAPS. Barcelona University. Barcelona. Functional unit of Clinical Immunology HSJD-HCP.Universidad de Barcelona. Pediatric Investigation Institute SJD, Barcelona, Spain, ²Hospital Universitari Vall d'Hebron, Barcelona, Spain, ³Rheumatology Department. Hospital Clínic Barcelona, Barcelona, Catalonia, Spain, ⁴Rheumatology Department. Vall d'Hebron University Hospital, Barcelona, Spain, Barcelona, Spain, ⁵Matern-Infantile Department, Hospital Clínic of Barcelona. Barcelona. Spain, Barcelona, Spain, ⁶Arthritis Unit. Rheumatology Department. Hospital Clinic of Barcelona. Barcelona. Spain, Barcelona, Spain, ⁷Neonatology Department. Vall d'Hebron University Hospital, Barcelona, Spain, Barcelona, Spain, ⁸Hospital d'Igualada, Barcelona, ⁹Hospital Universitari Vall d'Hebron, Barcelona, ¹⁰Hospital Sant Joan de Déu, Barcelona, Spain
Background/Purpose: Up to half of pregnant patients with rheumatic diseases experience disease activity which can increase the risk of pregnancy complications and poor disease outcomes. Treatment…
Abstract Number: 1273 • 2019 ACR/ARP Annual Meeting
Certolizumab Therapy in Patients with Uveitis During Pregnancy: Multicenter Study
DIANA PRIETO- PENA¹, Vanesa Calvo Río ², Mónica Calderón-Goercke ³, Olga Maíz Alonso ⁴, JR Jimenez-Aberasturi ⁵, Raul Veroz ⁶, Maria Soledad Blanco ⁷, José Manuel Santos ⁸, Francisco Navarro ⁹, Adela Gallego ¹⁰, Rosalia Demetrio ¹¹, Victor Manuel Martínez Taboada ¹¹, Miguel Angel González-Gay ¹² and Ricardo Blanco ², ¹Rheumatology, Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain, ²Rheumatology, Hospital Universitario Marques de Valdecilla, Santander, Spain, ³Hospital Marqués de Valdecilla, Santander, Cantabria, Spain, ⁴H. Donostia, San Sebastián, Spain, ⁵HU Araba, Vitoria, Spain, ⁶H. Mérida, Merida, Spain, ⁷H. Galdakano, Bilbao, Spain, ⁸H. Río Hortega, Valladolid, Spain, ⁹H.Elche, Alicante, Spain, ¹⁰H. Badajoz, Badajoz, Spain, ¹¹Hospital Universitario Marqués de Valdecilla, Santander, Spain, ¹²Universidad de Cantabria and IDIVAL, Hospital Universitario Marqués de Valdecilla, Santander, Spain
Background/Purpose: Uveitis often occur in women who are in their reproductive years. The management of uveitis during pregnancy is a challenge, making the physician to…
Abstract Number: 1761 • 2019 ACR/ARP Annual Meeting
The Prospective Open Label Preventive Approach to Congenital Heart Block with Hydroxychloroquine (PATCH) Study Demonstrates a Reduction in the Recurrence Rate of Advanced Block
Peter Izmirly¹, Mimi Kim ², Nathalie Costedoat-Chalumeau ³, Deborah Friedman ⁴, Amit Saxena ⁵, Joshua Copel ⁶, Rebecca Cohen ¹, Mala Masson ¹, Tishaun Middleton ¹, Kimberly Robins ¹, Robert Clancy ¹ and Jill Buyon ¹, ¹NYU School of Medicine, New York, ²Albert Einstein College of Medicine, Bronx, NY, ³Cochin University Hospital, Paris, France, ⁴New York Medical College, Valhalla, ⁵New York University School of Medicine, New York, NY, ⁶Yale School of Medicine, New Haven
Background/Purpose: Based on encouraging bench to bedside results including experimental evidence supporting Toll-like receptor signaling in the pathogenesis of CHB, a case control study demonstrating…
Abstract Number: 1896 • 2019 ACR/ARP Annual Meeting
Breastfeeding in Women with Rheumatic Diseases
Naira Ikram¹, Amanda Eudy ¹ and Megan Clowse ¹, ¹Duke University, Durham
Background/Purpose: For many women, breastfeeding is a central aspect of motherhood, but many worry that their rheumatic disease or treatment will interfere. Fortunately, most anti-rheumatic…
Abstract Number: 1899 • 2019 ACR/ARP Annual Meeting
sFlt-1, PlGF and VEGF in the Differential Diagnosis Between Active SLE Nephritis During Pregnancy and Preeclampsia
Guilherme De Jesus¹, Marcela Lacerda ¹, Bruna Rodrigues ¹, Flavia dos Santos ¹, Adriana Nascimento ¹, Luis Cristóvão Porto ¹, Nilson Ramires de Jesús ¹, Roger Levy ² and Evandro Klumb ¹, ¹Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, ²GlaxoSmithKline, Upper Providence, PA
Background/Purpose: Pregnancy in patients with SLE is associated with significant morbidity and mortality. SLE activity during pregnancy, specifically nephritis, makes the differential diagnosis with preeclampsia…
Abstract Number: 1900 • 2019 ACR/ARP Annual Meeting
Assessing Commercial Titers of anti-Ro60 and Ro52 Antibodies to Risk Stratify Surveillance of Anti-Ro/SSA Antibody Positive Pregnancies
Kimberly Robins ¹, Rohit Bhan¹, Catherine Trad ¹, Rebecca Cohen ¹, Miao Chang ¹, Benjamin Wainwright ¹, Mala Masson ¹, Shilpi Mehta-Lee ¹, Peter Izmirly ¹, Robert Clancy ¹, Bettina Cuneo ² and Jill Buyon ¹, ¹NYU School of Medicine, New York, ²Children's Hospital Colorado, Aurora
Background/Purpose: Pregnancy counseling of all anti-Ro positive women includes advice regarding the development of congenital heart block (CHB), albeit the risk is only 2% for…
Abstract Number: 1901 • 2019 ACR/ARP Annual Meeting
Serious Infections in Offspring Exposed in Utero to Non-TNFi Biologics and Tofacitinib
Evelyne Vinet¹, Yvan St-Pierre ¹, Cristiano S. Moura ¹, Jeffrey Curtis ² and Sasha Bernatsky ³, ¹McGill University Health Centre, Montreal, QC, Canada, ²University of Alabama at Birmingham, Birmingham, AL, ³Research Institute of the McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: During pregnancy, maternal circulating immunoglobulins G (IgG) are actively transported across the placenta through their Fc portion. Thus, TNFi and other biologics harbouring an Fc…
Abstract Number: 2414 • 2018 ACR/ARHP Annual Meeting
The Global Antiphospholipid Syndrome Score in Women with Systemic Lupus Erythematosus and Adverse Pregnancy Outcomes
Karen Schreiber¹, Massimo Radin², Irene Cecchi³, Elena Rubini⁴, Dario Roccatello⁵, Søren Jacobsen⁶, Maria Jose Cuadrado⁷ and Savino Sciascia⁸, ¹Department of Thrombosis and Haemophilia, Guy's and St Thomas' Hospital, London, United Kingdom., London, United Kingdom, ²Department of Clinical and Biological Sciences, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, ³Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, ⁴Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin and S. Giovanni Bosco Hospital, Turin, Italy., Turin, Italy, ⁵Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin and S. Giovanni Bo, Turin, Italy, ⁶University of Copenhagen, Copenhagen, Denmark, ⁷Clinica Universidad de Navarra, Madrid, Spain, ⁸Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Torino, Italy
Background/Purpose: Systemic lupus erythematosus (SLE) and antiphospholipid antibodies (aPL) are associated with pregnancy complications. Methods: 143 women ever pregnant with SLE who presented in our…
Abstract Number: 2421 • 2018 ACR/ARHP Annual Meeting
Pregnancy Outcomes in Women with Rheumatic Diseases and Thrombophilia Treated in a Multidisciplinary Unit
Isabel Añón Oñate¹, Irene Notario¹, Miguel Ángel Ferrer¹, Lorena Pérez¹, María Ramírez¹ and Rafael Cáliz², ¹Rheumatology, Hospital Universitario Virgen de las Nieves, Granada, Spain, ²Hospital Universitario Virgen de las Nieves, Granada, Spain
Background/Purpose: To evaluate the efficacy of the treatment on the pregnancy outcomes of women with Rheumatic Diseases and Thrombophilia from a Spanish cohort. Their pregnancies…
Abstract Number: 2426 • 2018 ACR/ARHP Annual Meeting
Defining a Standardized Core Data Set for Pregnancy Registers in Rheumatic Diseases – an European Approach
Yvette Meißner¹, Anja Strangfeld¹, Nathalie Costedoat-Chalumeau^2,3, Frauke Förger^4,5, Anna Moltó⁶, Marianne Wallenius^7,8 and Rebecca Fischer-Betz⁹, ¹Programme Area Epidemiology, German Rheumatism Research Center, Berlin, Germany, ²Université Paris-Descartes, Paris, France, ³Internal Medicine, Hopital Cochin, Paris, France, ⁴University of Bern, Bern, Switzerland, ⁵Rheumatology, Clinical Immunology and Allergology, Inselspital-University Hospital, Bern, Switzerland, ⁶Rheumatology B Department, Paris Descartes University, Cochin Hospital, AP-HP,Paris, Paris, France, ⁷Norwegian University of Science and Technology, Trondheim, Norway, ⁸St. Olav's University Hospital, Trondheim, Norway, ⁹Department of Rheumatology and Hiller Research Unit, University Hospital Duesseldorf, Duesseldorf, Germany
Background/Purpose: Robust data on the outcomes of pregnancy and influence of drug exposure in various inflammatory rheumatic diseases (IRD) are needed. Joint analyses of data…
Abstract Number: 2427 • 2018 ACR/ARHP Annual Meeting
Adequate Vaccine Response According to the Italian Schedule Among the Offspring of Women Affected By Rheumatoid Arthritis and Treated throughout Pregnancy By Certolizumab Pegol: Case Series
Marianna Meroni¹, Maria De Santis², Elena Generali², Angela Ceribelli³, Marta Caprioli³, Giacomo Maria Guidelli², Natasa Isailovic², Gaetano Maria Fara⁴, Carlo Selmi² and Maurizio Cutolo⁵, ¹Rheumatology and Clinical Immunology, Humanitas Research Hospital, Rozzano, Italy, ²Rheumatology and Clinical Immunology Unit, Humanitas Research Hospital, Rozzano (MI), Italy, ³Rheumatology and Clinical Immunology, Humanitas Research Hospital, Rozzano (MI), Italy, ⁴Department of Public Health and Infectious Diseases, "Sapienza" University of Rome, Rome, Italy, ⁵Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, San Martino Polyclinic Hospital, Genoa, Italy, Genoa, Italy
Background/Purpose: Certolizumab pegol (CTZ) is a TNFα inhibitor indicated for the treatment of women affected by rheumatoid arthritis (RA) throughout the whole pregnancy. Some concern,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].